Divi’s Lab share hits life-time HIGH, soars nearly 4% on Nifty—here is why
For the year 2021, Divi's Laboratories has earned consolidated total revenue of Rs 7032 cr for the financial year 2020-21 as against Rs 5584 cr during the previous year, reflecting a growth of 26%. PBT for the current year grew by 47% to 2666 cr as against a PBT of Rs 1819 cr for the previous year. PAT for the year amounted to Rs 1984 cr as against a PAT of Rs 1377 cr for the last year, reflecting a growth of 44%
For the year 2021, Divi's Laboratories has earned consolidated total revenue of Rs 7032 cr for the financial year 2020-21 as against Rs 5584 cr during the previous year, reflecting a growth of 26%. PBT for the current year grew by 47% to 2666 cr as against a PBT of Rs 1819 cr for the previous year. PAT for the year amounted to Rs 1984 cr as against a PAT of Rs 1377 cr for the last year, reflecting a growth of 44%.
Divi’s Laboratories has a solid base in the industry, Divi's Laboratories is extending its product offerings in the generic API segment, developing 16 additional APIs to lead the next phase of growth and the subsequent DMF filing. Divi’s Laboratories has more than doubled its capacity and is poised to take advantage of carotenoids' growing market. Divi’s Laboratories is well poised to take advantage of the carotenoid opportunity, with a 21% revenue CAGR to Rs 8 bn forecast over FY20–23, attributes to solid demand, product offerings, and advanced manufacturing.
See Zee Business Live TV Streaming Below:
During FY18–20, Divi’s Laboratories more than doubled its revenue in the Carotenoids industry to Rs 4.4 bn (8% of sales) and saw a 22% YoY rise in 9M FY21. With a CAGR of 4%, the global carotenoid market is worth USD 1.5 bn by 2026. Technically with a break of the downward sloping trend line, the stock has generated a buy signal for next week.
Established in 1990, Divi’s Laboratories is engaged in the manufacture of generic APIs and intermediates, custom synthesis of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds.
ICICI Securities expect CS to grow at a CAGR of 24% to Rs 4203 cr in FY20-23E. Divi’s Laboratories remains committed to a few research driven niche opportunities as was the case when it started commercial operations. Two generics, Naproxen (pain management) and Dextromethorphan (cough suppressant) account for 26% of overall revenues. Divi’s Laboratories enjoys 70% global market share in these two products.
ICICI Securities expects sales from generics to grow at a CAGR of 23% to Rs 5954 cr in FY20-23E. More than strong quarterly performance (the management stresses in a business like this can be lumpy) , the important narrative for Divi’s Laboratories is unprecedented capex to further augment capacities besides preparing for growing opportunities arising from China plus one factor. It has earmarked aggressive capex of Rs 3700 cr [| 1800 (existing plans) + | 400 (custom synthesis blocks) + Rs 1500 crore (greenfield Kakinada plant)], over and above Rs 2000 crore spent in the last five years.
Sharekhan says that Divis Laboratories is expected to benefit from strong growth likely in the global active pharmaceutical ingredients (API) space, driven by multiple factors. Increasing preference for biologics for disease management, key drugs going off patent, outsourcing opportunities and higher regulatory approvals would be key growth drivers for the API industry, which is expected to report a high single-digit CAGR over the next 6-7 years. In addition to this, there are immense opportunities that have emerged for API players such as Divis Laboratories
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.